New drugs launched since 2009 accounted for nearly one quarter of brand-name drug sales in Canada by 2016, according to a report from the Patented Medicine Prices Review Board (PMPRB). As well, in line with trends observed from 2009 to 2014, the study finds that high-priced specialty drugs - such as those used to treat rare diseases and biologic drugs and oncology drugs - continue to dominate the new drug landscape in 2015 and 2016. Orphan drugs are increasingly dominating the new drug landscape, representing 54% of new drugs entering the market in 2015 and 42% in 2016, a significant increase from the 33% average from 2009 to 2014. The number of oncology drugs continues to be high, representing 26% of the total new drugs in 2015 and 2016. It also shows many new drugs come with a high cost, as 35% of those launched in 2015 were oncology drugs with a treatment cost exceeding $5,000 for a 28-day treatment, while 30% were non-oncology drugs with treatment costs exceeding $10,000 per year. Between 2009 and 2015, Canada placed 11th in the OECD in terms of the number of new drugs launched, behind all the other PMPRB7 countries, many of which had lower average patented drug prices.
Autres:
Les médicaments de spécialité à prix élevé continuent de dominer le paysage des nouveaux médicaments - Conseil d'examen du prix des médicaments brevetés
NBHC Sustainability